Notably, the pan-CLK DYRK inhibitors lorecivivint (NCT04520607) and cirtuvivint (NCT05084859) have entered clinical trials for the treatment of knee osteoarthritis and cancer, respectively. Here, DYRK1A is linked to osteoarthritis, knee.